Screener
Regeneron Pharmaceuticals REGN Contract Liabilities
Contract Liabilities at other companies
Other financials
Where this comes from
Reported directly by Regeneron Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:ContractWithCustomerLiabilityNoncurrent.
The source filing: Regeneron Pharmaceuticals’s 10-Q, filed July 30, 2026.
- Filed
- Jul 30, 2026, 6:52 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0000872589-26-000025
| Line item | June 30, 2026 | December 31, 2025 |
|---|---|---|
| Total current liabilities | 5,530.6 | 4,368.4 |
| Long-term debt | 1,986.6 | 1,985.9 |
| Finance lease liabilities | — | 720.0 |
| Deferred revenue | 220.4 | 208.7 |
| Other noncurrent liabilities | 2,281.6 | 2,018.8 |
| Total liabilities | 10,019.2 | 9,301.8 |
| Stockholders' equity: | ||
| Preferred Stock, par value $.01 per share; 30.0 shares authorized; shares issued and outstanding - none | — | — |
Item 1. Financial Statements (unaudited)
FAQ
- What is Regeneron Pharmaceuticals's contract liabilities?
- Regeneron Pharmaceuticals (REGN) reported contract liabilities of $220.4M in Q2 2026.
- What does contract liabilities mean?
- Revenue collected or billed in advance of performance — deferred revenue under ASC 606 terminology, representing future revenue obligations.
Ask your AI about Regeneron Pharmaceuticals's contract liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude